Li Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Li Li has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Xiaodong Wang
Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, China, China
3 shared publications - Boyan Zhou
Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, China, China
1 shared publication - Donghao Lu
Health Management Center, General Practice Medical Center, Innovation Institute for Integration of Medicine and Engineering, West China Hospital, Sichuan University, Chengdu, China
1 shared publication - Huan Song
Sichuan University
1 shared publication Junhua Wu
Radiology, West China Hospital, Chengdu, China
1 shared publication- Lei Deng
Division of Hematology and Oncology, Department of Medicine, School of Medicine, University of Washington, Seattle, WA 98195, USA
1 shared publication
Latest Publications
- Open Access
- 12 November 2026
- Published by MDPI AG in Preprints.org
Shifting Burden from Mortality to Morbidity: Global Trends and Disparities in Colorectal Cancer Years Lived with Disability, 1990–2023
Background/Objectives: As survival after colorectal cancer improves, more patients live with the consequences of the disease and its treatment, yet years lived with disability (YLDs) are rarely analysed as a primary outcome. We examined whether the colorectal cancer burden is shifting from premature death towards life with disability. Methods: Using Global Burden of Disease (GBD) 2023 estimates for the world, the five Socio-demographic Index (SDI) quintiles and China, we analysed YLDs, years of life lost (YLLs) and the age-standardised YLD share of disability-adjusted life-years (morbidity share) from 1990 to 2023 with joinpoint regression, and decomposed the change in YLD counts into population growth, population ageing and change in age-specific rates. Results: Global YLDs rose from 434,965 to 1,125,290 (+158.7%); the age-standardised YLD rate rose by 10.5% while the YLL rate fell by 22.1%. The morbidity share increased from 3.06% to 4.28% globally and from 2.06% to 4.69% in China, which overtook the global level in 2018. A rising YLD rate with a falling YLL rate was found globally, in the two higher SDI quintiles and in China; in the three lower quintiles both rates rose. The global increase in the YLD rate was confined to men (+19.8%; women −1.5%). Population growth and ageing accounted for 43.4% and 45.9% of the global increase in YLD counts. Conclusions: In higher-SDI settings and in China, the colorectal cancer burden is shifting from premature death towards life with disability, whereas in lower-SDI settings both components are still rising. Survivorship services should be planned for a disability burden concentrated among men and older adults.
- 12 November 2026
- Published by MDPI AG in Preprints.org
Open AccessShifting Burden from Mortality to Morbidity: Global Trends and Disparities in Colorectal Cancer Years Lived with Disability, 1990–2023
Background/Objectives: As survival after colorectal cancer improves, more patients live with the consequences of the disease and its treatment, yet years lived with disability (YLDs) are rarely analysed as a primary outcome. We examined whether the colorectal cancer burden is shifting from premature death towards life with disability. Methods: Using Global Burden of Disease (GBD) 2023 estimates for the world, the five Socio-demographic Index (SDI) quintiles and China, we analysed YLDs, years of life lost (YLLs) and the age-standardised YLD share of disability-adjusted life-years (morbidity share) from 1990 to 2023 with joinpoint regression, and decomposed the change in YLD counts into population growth, population ageing and change in age-specific rates. Results: Global YLDs rose from 434,965 to 1,125,290 (+158.7%); the age-standardised YLD rate rose by 10.5% while the YLL rate fell by 22.1%. The morbidity share increased from 3.06% to 4.28% globally and from 2.06% to 4.69% in China, which overtook the global level in 2018. A rising YLD rate with a falling YLL rate was found globally, in the two higher SDI quintiles and in China; in the three lower quintiles both rates rose. The global increase in the YLD rate was confined to men (+19.8%; women −1.5%). Population growth and ageing accounted for 43.4% and 45.9% of the global increase in YLD counts. Conclusions: In higher-SDI settings and in China, the colorectal cancer burden is shifting from premature death towards life with disability, whereas in lower-SDI settings both components are still rising. Survivorship services should be planned for a disability burden concentrated among men and older adults.
- Open Access
- 21 October 2023
- Published by MDPI AG in Current Oncology
- Vol. 30 (10) , 9346-9356
Guideline- Versus Non-Guideline-Based Neoadjuvant Management of Clinical T4 Rectal Cancer
(1) Background: Practice guidelines recommend neoadjuvant treatment for clinical T4 rectal cancer. The primary objective of this retrospective study was to assess whether compliance with guidelines correlates with patient outcomes. Secondarily, we evaluated predictors of adherence to guidelines and mortality. (2) Methods: A total of 397 qualified rectal cancer (RC) patients from 2017 to 2020 at West China Hospital of Sichuan University were included. Patients were divided into two groups depending on adherence to neoadjuvant treatment guidelines. The main endpoints were overall survival (OS) and disease special survival (DSS). We analyzed factors associated with guideline adherence and mortality. (3) Results: Compliance with guidelines was only 39.55%. Patients’ neoadjuvant therapy treated not according to the guidelines for clinical T4 RC was not associated with an overall survival (95.7% vs. 88.9%) and disease special survival (96.3% vs. 91.1%) benefit. Patients were more likely to get recommended therapy with positive patient compliance. Staging Ⅲ, medium/high differentiation and objective compliance were associated with increased risk of mortality. (4) Conclusions: Guideline adherence for clinical T4 RC in our system is low. Compliance with the relevant guidelines for neoadjuvant therapy seems not to lead to better overall survival for patients with clinical T4 RC.
- 21 October 2023
- Published by MDPI AG in Current Oncology
- Vol. 30 (10) , 9346-9356
Open AccessGuideline- Versus Non-Guideline-Based Neoadjuvant Management of Clinical T4 Rectal Cancer
(1) Background: Practice guidelines recommend neoadjuvant treatment for clinical T4 rectal cancer. The primary objective of this retrospective study was to assess whether compliance with guidelines correlates with patient outcomes. Secondarily, we evaluated predictors of adherence to guidelines and mortality. (2) Methods: A total of 397 qualified rectal cancer (RC) patients from 2017 to 2020 at West China Hospital of Sichuan University were included. Patients were divided into two groups depending on adherence to neoadjuvant treatment guidelines. The main endpoints were overall survival (OS) and disease special survival (DSS). We analyzed factors associated with guideline adherence and mortality. (3) Results: Compliance with guidelines was only 39.55%. Patients’ neoadjuvant therapy treated not according to the guidelines for clinical T4 RC was not associated with an overall survival (95.7% vs. 88.9%) and disease special survival (96.3% vs. 91.1%) benefit. Patients were more likely to get recommended therapy with positive patient compliance. Staging Ⅲ, medium/high differentiation and objective compliance were associated with increased risk of mortality. (4) Conclusions: Guideline adherence for clinical T4 RC in our system is low. Compliance with the relevant guidelines for neoadjuvant therapy seems not to lead to better overall survival for patients with clinical T4 RC.
- Open Access
- 18 November 2009
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 25 (3) , 351-358
Multimodal preoperative evaluation system in surgical decision making for rectal cancer: a randomized controlled trial
Multimodal preoperative evaluation (MPE) is a novel strategy for surgical decision making, incorporating the transrectal ultrasound (TRUS), 64 multi-slice spiral computer tomography (MSCT), and serum amyloid A protein (SAA) for rectal cancer. This trial aims to determine the accuracy of MPE in preoperative staging and its role in surgical decision making for rectal cancer. Two hundred twenty-five participants with histologically proven rectal cancer with tumor height less than 10 cm were randomly assigned into three arms in the ratio 1:1:1. Arm A (MPE) was multimodal staged by the combination of MSCT, TRUS, and SAA. Arm B (MSCT + SAA) was staged by MSCT and SAA. Arm C (MSCT) was staged only by MSCT. The primary endpoints were the accuracy of preoperative staging and expected surgical procedures. This study is registered as an International Standard Randomised Controlled Trial, number ChiCTR-DT-00000409. The analysis showed statistical difference in the accuracy of T staging between arm A and B (94.6% vs. 77.8%, P = 0.003) and arm A and C (94.6% vs. 80.6%, P = 0.010). Statistical difference was also observed between the accuracies of preoperative N staging between arm A and C (85.1% vs. 69.4%, P = 0.023) and arm A and B (85.1% vs. 84.7%, P = 0.029). Surgical decision making in arm A was more accurate than that in arm C (95.9% vs. 80.6%, P = 0.001). Pathological T stage (P < 0.001), N stage (P < 0.001), tumor node metastasis stage (P < 0.001), serum level of SAA (P = 0.002), and tumor height (P = 0.030) were significantly associated with final surgical procedures. MPE is an effective strategy in preoperative staging and more accurate than other available strategies in surgical decision making for rectal cancer.
- 18 November 2009
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 25 (3) , 351-358
Open AccessMultimodal preoperative evaluation system in surgical decision making for rectal cancer: a randomized controlled trial
Multimodal preoperative evaluation (MPE) is a novel strategy for surgical decision making, incorporating the transrectal ultrasound (TRUS), 64 multi-slice spiral computer tomography (MSCT), and serum amyloid A protein (SAA) for rectal cancer. This trial aims to determine the accuracy of MPE in preoperative staging and its role in surgical decision making for rectal cancer. Two hundred twenty-five participants with histologically proven rectal cancer with tumor height less than 10 cm were randomly assigned into three arms in the ratio 1:1:1. Arm A (MPE) was multimodal staged by the combination of MSCT, TRUS, and SAA. Arm B (MSCT + SAA) was staged by MSCT and SAA. Arm C (MSCT) was staged only by MSCT. The primary endpoints were the accuracy of preoperative staging and expected surgical procedures. This study is registered as an International Standard Randomised Controlled Trial, number ChiCTR-DT-00000409. The analysis showed statistical difference in the accuracy of T staging between arm A and B (94.6% vs. 77.8%, P = 0.003) and arm A and C (94.6% vs. 80.6%, P = 0.010). Statistical difference was also observed between the accuracies of preoperative N staging between arm A and C (85.1% vs. 69.4%, P = 0.023) and arm A and B (85.1% vs. 84.7%, P = 0.029). Surgical decision making in arm A was more accurate than that in arm C (95.9% vs. 80.6%, P = 0.001). Pathological T stage (P < 0.001), N stage (P < 0.001), tumor node metastasis stage (P < 0.001), serum level of SAA (P = 0.002), and tumor height (P = 0.030) were significantly associated with final surgical procedures. MPE is an effective strategy in preoperative staging and more accurate than other available strategies in surgical decision making for rectal cancer.